- Tliray’s (TLRY, Financial) research shows higher bioavailability of its oral THC:CBD extract than nabiximols.
- The study involved 12 healthy volunteers with no serious adverse events reported.
- Tliray Medical provides EU-GMP certified cannabis products to over 20 countries.
Tliray Medical (TLRY) has released groundbreaking research that demonstrates the superior bioavailability of its oral THC:CBD extract compared to nabiximols. This pilot crossover study was conducted with 12 healthy volunteers, evenly divided by gender, under fasting conditions. Results indicated significantly higher maximum concentrations (Cmax) of THC and CBD for the oral extract, with no significant differences in the time to maximum concentration (Tmax) or area under the curve (AUC) between the two formulations.
The study assessed the pharmacokinetic parameters of two delivery methods: oral administration of Tilray’s THC:CBD extract and oromucosal administration of nabiximols. Blood samples collected pre-dose and at 16 intervals post-dose over a 24-hour period revealed that, while both compounds became undetectable within 24 hours, the oral extract achieved higher Cmax levels. Additionally, nabiximols showed higher effectiveness in males compared to females.
This research not only advances the understanding of cannabinoid pharmacokinetics but also underscores Tilray’s commitment to developing effective medical cannabis solutions globally. Tilray Medical, a leading provider of EU-GMP certified pharmaceutical-grade cannabis products, currently supplies over 20 countries. Its comprehensive portfolio supports research in conditions such as pediatric epilepsy, cancer-induced nausea, and PTSD, among others.
